BR112020008705A2 - Métodos de tratamento da insuficiência cardíaca com fração de ejeção reduzida com dapagliflozina - Google Patents

Métodos de tratamento da insuficiência cardíaca com fração de ejeção reduzida com dapagliflozina

Info

Publication number
BR112020008705A2
BR112020008705A2 BR112020008705A BR112020008705A BR112020008705A2 BR 112020008705 A2 BR112020008705 A2 BR 112020008705A2 BR 112020008705 A BR112020008705 A BR 112020008705A BR 112020008705 A BR112020008705 A BR 112020008705A BR 112020008705 A2 BR112020008705 A2 BR 112020008705A2
Authority
BR
Brazil
Prior art keywords
heart failure
dapagliflozin
methods
ejection fraction
reduced ejection
Prior art date
Application number
BR112020008705A
Other languages
English (en)
Inventor
Maria Langkilde Anna
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of BR112020008705A2 publication Critical patent/BR112020008705A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Fodder In General (AREA)

Abstract

usos de composições farmacêuticas. a presente divulgação é dirigida a métodos de tratar pacientes com insuficiência cardíaca com fração de ejeção reduzida (icfer), com e sem diabetes do tipo 2, com um inibidor do sglt2, tal como a dapagliflozina. os métodos aqui divulgados podem reduzir o risco de um resultado composto de um primeiro episódio de agravamento da insuficiência cardíaca (hospitalização por insuficiência cardíaca ou uma visita urgente devida à insuficiência cardíaca) ou morte por causas cardiovasculares. cada um dos três componentes deste resultado composto também pode ser reduzido, bem como o número total de hospitalizações por insuficiência cardíaca e mortes de causas cardiovasculares. os inibidores do sglt2, tal como a dapagliflozina, também podem reduzir um agravamento dos sintomas de insuficiência cardíaca. os métodos aqui divulgados também podem melhorar os sintomas de insuficiência cardíaca, estado de saúde, e qualidade de vida.
BR112020008705A 2019-08-30 2020-03-09 Métodos de tratamento da insuficiência cardíaca com fração de ejeção reduzida com dapagliflozina BR112020008705A2 (pt)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201962893849P 2019-08-30 2019-08-30
US201962930673P 2019-11-05 2019-11-05
US201962946625P 2019-12-11 2019-12-11
US202062960756P 2020-01-14 2020-01-14
US202062969181P 2020-02-03 2020-02-03
US202062985407P 2020-03-05 2020-03-05
PCT/EP2020/056211 WO2021037400A1 (en) 2019-08-30 2020-03-09 Methods of treating heart failure with reduced ejection fraction with dapagliflozin

Publications (1)

Publication Number Publication Date
BR112020008705A2 true BR112020008705A2 (pt) 2022-03-22

Family

ID=69784449

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112020008705A BR112020008705A2 (pt) 2019-08-30 2020-03-09 Métodos de tratamento da insuficiência cardíaca com fração de ejeção reduzida com dapagliflozina

Country Status (18)

Country Link
US (2) US10973836B2 (pt)
EP (1) EP4021507A1 (pt)
JP (2) JP2022530575A (pt)
KR (2) KR102359799B1 (pt)
CN (1) CN112752582A (pt)
AU (3) AU2020202887B2 (pt)
BR (1) BR112020008705A2 (pt)
CA (1) CA3079175A1 (pt)
CL (1) CL2020001335A1 (pt)
CR (1) CR20200224A (pt)
IL (1) IL274020A (pt)
JO (1) JOP20200098A1 (pt)
MX (2) MX2020005388A (pt)
PE (1) PE20211267A1 (pt)
PH (1) PH12020551141A1 (pt)
SG (1) SG11202003971RA (pt)
TW (2) TW202335668A (pt)
WO (1) WO2021037400A1 (pt)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA202190226A1 (ru) 2018-07-19 2021-06-16 Астразенека Аб СПОСОБЫ ЛЕЧЕНИЯ HFpEF С ИСПОЛЬЗОВАНИЕМ ДАПАГЛИФЛОЗИНА И СОДЕРЖАЩИХ ЕГО КОМПОЗИЦИЙ
JP2022530575A (ja) 2019-08-30 2022-06-30 アストラゼネカ・アクチエボラーグ ダパグリフロジンを用いて、駆出率が低下した心不全を治療する方法
US20240100013A1 (en) * 2021-01-04 2024-03-28 Lexicon Pharmaceuticals, Inc. Sotagliflozin for improving left atrial function
WO2023144722A1 (en) 2022-01-26 2023-08-03 Astrazeneca Ab Dapagliflozin for use in the treatment of prediabetes or reducing the risk of developing type 2 diabetes
JP7396579B2 (ja) 2022-01-31 2023-12-12 壽製薬株式会社 左室駆出率が保たれた心不全に対する医薬組成物
WO2023175573A1 (en) * 2022-03-17 2023-09-21 Zydus Lifesciences Limited Pharmaceutical compositions comprising a β-blocker and an sglt2 inhibitor
WO2023192848A1 (en) * 2022-03-28 2023-10-05 University Of Maryland, Baltimore Methods and compositions for the treatment of stroke
WO2024047574A1 (en) * 2022-09-01 2024-03-07 Astrazeneca Ab Combination of sglt2 inhibitors and mineralcorticoid receptor modulators for use in treatment of cardiorenal diseases

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6515117B2 (en) 1999-10-12 2003-02-04 Bristol-Myers Squibb Company C-aryl glucoside SGLT2 inhibitors and method
PH12000002657B1 (en) 1999-10-12 2006-02-21 Bristol Myers Squibb Co C-aryl glucoside SGLT2 inhibitors
KR20080102395A (ko) 2006-02-15 2008-11-25 베링거 인겔하임 인터내셔날 게엠베하 글루코피라노실-치환된 벤조니트릴 유도체, 당해 화합물을 함유하는 약제학적 조성물, 이들의 용도 및 이들의 제조방법
PE20090185A1 (es) * 2007-03-22 2009-02-28 Bristol Myers Squibb Co Formulaciones farmaceuticas que contienen un inhibidor sglt2
TW200904454A (en) * 2007-03-22 2009-02-01 Bristol Myers Squibb Co Methods for treating obesity employing an SGLT2 inhibitor and compositions thereof
CA2812016A1 (en) 2013-04-05 2014-10-05 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
RS58274B1 (sr) * 2014-06-30 2019-03-29 Astrazeneca Ab Benzoksazinon amidi kao modulatori mineralokortikoidnog receptora
JP2017528499A (ja) * 2014-09-25 2017-09-28 アストラゼネカ・アクチエボラーグＡｓｔｒａｚｅｎｅｃａ Ａｋｔｉｅｂｏｌａｇ 肝臓の疾患を治療するためのオメガ３脂肪酸とｓｇｌｔ−２阻害薬との併用剤
JP7161405B2 (ja) 2016-03-16 2022-10-26 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング エンパグリフロジンを含む医薬組成物及びその使用
WO2018043463A1 (ja) * 2016-08-30 2018-03-08 国立大学法人新潟大学 老化細胞除去薬
WO2018142422A1 (en) 2017-02-02 2018-08-09 Indoco Remedies Limited Process for the preparation of dapagliflozin
KR101943382B1 (ko) 2017-09-19 2019-01-29 오토텔릭바이오 주식회사 Sglt-2 저해제 및 안지오텐신 수용체 차단제를 포함하는 의약 조성물
EA202190226A1 (ru) 2018-07-19 2021-06-16 Астразенека Аб СПОСОБЫ ЛЕЧЕНИЯ HFpEF С ИСПОЛЬЗОВАНИЕМ ДАПАГЛИФЛОЗИНА И СОДЕРЖАЩИХ ЕГО КОМПОЗИЦИЙ
JP2022530575A (ja) 2019-08-30 2022-06-30 アストラゼネカ・アクチエボラーグ ダパグリフロジンを用いて、駆出率が低下した心不全を治療する方法
WO2022022865A1 (en) * 2020-07-27 2022-02-03 Astrazeneca Ab Methods of treating chronic kidney disease with dapagliflozin

Also Published As

Publication number Publication date
JP2022530575A (ja) 2022-06-30
EP4021507A1 (en) 2022-07-06
TW202108134A (zh) 2021-03-01
WO2021037400A1 (en) 2021-03-04
IL274020A (en) 2021-03-01
CL2020001335A1 (es) 2021-07-09
KR102359799B1 (ko) 2022-02-09
CR20200224A (es) 2021-05-26
KR20220044234A (ko) 2022-04-07
US20210260083A1 (en) 2021-08-26
KR20210027229A (ko) 2021-03-10
JOP20200098A1 (ar) 2021-02-28
AU2020202887B2 (en) 2021-05-20
US11903955B2 (en) 2024-02-20
MX2022008018A (es) 2022-07-27
MX2020005388A (es) 2022-10-25
CA3079175A1 (en) 2021-02-28
PH12020551141A1 (en) 2021-05-31
US10973836B2 (en) 2021-04-13
TW202335668A (zh) 2023-09-16
AU2020202887A1 (en) 2021-03-18
AU2021215150A1 (en) 2021-09-02
US20210060043A1 (en) 2021-03-04
JP2023025207A (ja) 2023-02-21
SG11202003971RA (en) 2021-04-29
AU2021215150B2 (en) 2023-05-04
TWI786398B (zh) 2022-12-11
PE20211267A1 (es) 2021-07-19
CN112752582A (zh) 2021-05-04
AU2023210548A1 (en) 2023-08-17

Similar Documents

Publication Publication Date Title
BR112020008705A2 (pt) Métodos de tratamento da insuficiência cardíaca com fração de ejeção reduzida com dapagliflozina
Popov Mitochondrial biogenesis: An update
Abbate et al. Interleukin‐1 blockade inhibits the acute inflammatory response in patients with ST‐segment–elevation myocardial infarction
Gilat et al. Obstructive sleep apnea and cardiovascular comorbidities: a large epidemiologic study
Argilés et al. Muscle wasting in cancer: the role of mitochondria
Gollob et al. Novel PRKAG2 mutation responsible for the genetic syndrome of ventricular preexcitation and conduction system disease with childhood onset and absence of cardiac hypertrophy
BR112014012808A2 (pt) proteína de fusão anticâncer
Na et al. Cervical ganglion block attenuates the progression of pulmonary hypertension via nitric oxide and arginase pathways
NO20080487L (no) Rekominant interferona2 (IFNa2) mutanter
Boström et al. Impact of exercise on muscle and nonmuscle organs
CL2020001742A1 (es) Inhibidores de glicolato oxidasa para el tratamiento de enfermedades
Rafanelli et al. Is depression the wrong treatment target for improving outcome in coronary artery disease?
CL2020002940A1 (es) Uso de benzamidas sustituidas con 1,3-tiazol-2-ilo para el tratamiento de enfermedades asociadas con la sensibilización de las fibras nerviosas
BR112015009072A2 (pt) métodos para redução dos riscos associados à insuficiência cardíaca e fatores associados à mesma
Procopio et al. Role of adenosine and purinergic receptors in myocardial infarction: focus on different signal transduction pathways
BR112021006488A2 (pt) compostos e composições para o tratamento de condições associadas com atividade do receptor apj
Yang et al. Continuous blood purification ameliorates endothelial hyperpermeability in SAP patients with MODS by regulating tight junction proteins via ROCK
BR112015031416A2 (pt) métodos para a promoção do desenvolvimento e/ou da saúde neuronal compreendendo a administração de uma combinação de ácido docosa-hexaenoico e ácido alfa-lipoico
Kuntic et al. Impact of air pollution on cardiovascular aging
Ivanovic et al. When does low normal blood pressure become too low? The J-curve phenomenon
AR118963A1 (es) Métodos de tratamiento de la insuficiencia cardíaca con fracción de eyección reducida con dapagliflozina
EA202090875A1 (ru) Способы лечения сердечной недостаточности со сниженной фракцией выброса с помощью дапаглифлозина
BR112021019182A2 (pt) Oligonucleotídeos angptl2 antissenso e seus usos
Bortolozzi et al. New advances in the pharmacology and toxicology of lithium: a neurobiologically-oriented overview.
Jollant Add-on lithium for the treatment of unipolar depression: Too often forgotten?